title: Translating cancer genomes sequencing revolution into surgical oncology practice.
abstract: BACKGROUND
  Ten years after the first complete human genome sequencing, next-generation sequencing (NGS) technology has revolutionized genomics and biomedical research. Here we discuss potential emerging and future applications of NGS platforms and how cancer genome advances may change current surgical oncology practice.
  
  
  METHODS
  Publications in PubMed with partial or complete human and cancer genome sequencing over the last decade have been retrieved and analyzed. Recently launched international large-scale consortiums for systematic study of causal (driver) mutations underlying common complex diseases such as cancer and more recent opinion articles by leading scientists have been considered to predict the prospects of integration genomics data into surgical oncology.
  
  
  RESULTS
  Two dozen complete human genome sequences, and three full-genome sequencing in three cancer patients have recently been published. These studies and other cancer genome systematic studies evaluating genomic rearrangements and copy-number changes consistently reveal that cancer initiation and metastasis are much more complex than we thought. This high complexity and widespread variability of cancer genes, mutations, and deregulated signaling pathways among patients with the same cancer type, tumor stage, and clinicopathologic features explains the limited effectiveness of currently used biologically targeted agents.
  
  
  CONCLUSIONS
  Yet the impact of genomics explosion in surgical oncology is little. Nevertheless, "big" biology consortiums such as the International Cancer Genome Project and other systematic studies in the areas of genetics, genomics, and epigenetics are now providing in-depth understanding of cancer, and shape new more rational ways towards novel therapeutics for improving oncologic outcomes of millions of patients worldwide. At the beginning of the second post-genomic decade, an explosion in genomic technology has revolutionized biomedical sciences. The ability of latest DNA sequencing technology to identify, in an unprecedented level, causal mutations driving cancer initiation and metastasis raises significant expectations for improving oncologic outcomes. Which are the challenges and perspectives to translate this genomic revolution into a surgical oncology-changing era?
authors.affiliation: Department of Surgery, Ioannina University School of Medicine, Ioannina, Greece.
authors.forename: Christos
authors.initials: C
authors.lastname: Katsios
authors.forename: Dimosthenis E
authors.initials: DE
authors.lastname: Ziogas
authors.forename: Theodore
authors.initials: T
authors.lastname: Liakakos
authors.forename: Odysseas
authors.initials: O
authors.lastname: Zoras
authors.forename: Dimitrios H
authors.initials: DH
authors.lastname: Roukos
mesh_terms: D044127:Epigenesis, Genetic; D005820:Genetic Testing; D023281:Genomics / Q000639:trends*; D006801:Humans; D008495:Medical Oncology / Q000639:trends*; D058990:Molecular Targeted Therapy